As the M&A market continues to strengthen and cross-border activity accelerates, industry participants are actively exploring new opportunities outside of their home markets as core to their strategic growth plans.
Join us for a panel discussion featuring Clifford Chance practitioners, who will offer perspectives from Europe and the United States on cross-border M&A through the US/European investment corridor, with a focus on US outbound investment.
You will also hear from Alison O’Neill, Vice President and Chief Counsel, Strategic Transactions & Digital at Pfizer, who will join us for a fireside chat. Alison leads the company’s most significant M&A, licensing, and partnership deals globally. She will discuss how successfully navigating cross-border M&A requires practical, actionable legal advice, adaptability to local regulations and cultures, and strong communication to help teams operate confidently outside their home markets.
This event is open to legal, corporate development, financial and other M&A advisory teams, and is appropriate for all levels of experience.
US CLE credit is pending.
Agenda highlights:
Legal and Commercial Risks: Know what to expect when looking to acquire European targets.
Deal Term Convergence: Explore the similarities and differences between US and European M&A deal terms, such as MAC clauses and pricing mechanics.
Competitive Landscape: Discover strategies to stay competitive on European deals.
Work Council Requirements: Find out how work council requirements can disrupt deals in Europe and what you can do to manage challenges.
AI and Data Considerations: Gain insights into AI and data and their impact on due diligence, deal valuation, and regulatory/antitrust matters in Europe.
